Humana Inc. – Recent Corporate and Market Developments

Date: 6 March 2026

1. Credit Rating Announcement

The American insurance‑rating agency AM Best has assigned a new junior subordinated notes credit rating to Humana Inc. The decision, reported on 6 March 2026, reflects the agency’s assessment of the company’s creditworthiness in connection with its recently issued subordinated debt. The rating is intended to inform investors and creditors about the relative risk associated with the notes.

2. Share‑Price Performance and Investment Return

  • Historical Context: On 5 March 2021, Humana shares were priced at $399.39 per share. An investment of $100 at that time would have yielded 0.250 shares today.
  • Current Value: The share closed at $180.75 on 5 March 2026, a decline of 54.74 % over the five‑year period.
  • Market Capitalization: Humana’s equity value stands at approximately $22 billion, underscoring its status as a significant player in the health‑care services sector.

3. Corporate Governance and Shareholder Communications

3.1. Definitive Proxy Statements

  • DEF 14A Filing (2026‑01): The company filed a definitive proxy statement (Accession Number 0001104659‑26‑024393) detailing shareholder proposals and voting procedures.
  • Other DEF 14A Filing (2026‑02): A subsequent proxy statement (Accession Number 0001104659‑26‑024799) was submitted, providing updated information for the upcoming annual meeting.

3.2. Prospectus

  • Rule 424(b)(5) Prospectus (2026‑01): Humana released a prospectus (Accession Number 0001628280‑26‑015644) in accordance with SEC Rule 424(b)(5), outlining the company’s financial condition, business strategy, and risk factors. The prospectus is available on the SEC website for public inspection.

4. Dividend and Distribution Update

A recent announcement from HUMM GROUP LIMITED (entity code 122574583, ASX code HUM) updated the dividend distribution for ordinary fully‑paid shares. The update, dated 6 March 2026, added the Dividend Reinvestment Plan (DRP) price based on a five‑day volume‑weighted average price (VWAP) calculated up to 5 March 2026. The distribution pertains to a six‑month period, with details of the payout scheduled to follow the company’s next financial reporting.

5. Market Position and Financial Snapshot

  • Sector: Health Care Providers & Services
  • Primary Exchange: New York Stock Exchange
  • Currency: USD
  • Close Price (5 March 2026): $179.15
  • 52‑Week Range: $169.61 (low) – $315.35 (high)
  • Price‑to‑Earnings Ratio: 18.43
  • Market Cap: $21.6 billion

These data points provide investors with a comprehensive view of Humana’s current market valuation and recent corporate actions. The company’s ongoing engagement with regulatory bodies, transparent dividend practices, and credit rating activity signal active management of its financial and governance profile.